| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/18/2002 | US20020044943 Mucin MUC-1; including organ transplant rejection or graft versus host disease |
| 04/18/2002 | US20020044942 Transfer factor composition and process for producing same |
| 04/18/2002 | US20020044941 Nucleic acids, proteins and antibodies |
| 04/18/2002 | US20020044940 Novel saponin compositions and uses thereof |
| 04/18/2002 | US20020044939 Or Escherichia coli (E. coli) heat labile toxin where in the amino acid sequence, serine-63 and arginine-192 are replaced by another amino acid; vaccines against Vibrio cholera and enterotoxigenic strain of E. coli |
| 04/18/2002 | US20020044938 Compositions and methods for the treatment of inflammatory bowel disease |
| 04/18/2002 | US20020044937 Where the protein binds to T-cell cell surface protein, and that complex with nucleic acids, for transporting nucleic acids into human or animal cells which express the T-cell surface protein; antisense therapy, HIV therapy |
| 04/18/2002 | US20020044936 Administering a monoclonal antibody or fragment thereof which acts as an antagonist of the integrins GPIIb/IIIa ( alpha IIb beta 3) and alpha v beta 3; also treating inflammatory diseases such as rheumatoid arthritis, psoriasis |
| 04/18/2002 | US20020044933 Inhibition of intimal hyperplasia using antibodies to PDGF receptors |
| 04/18/2002 | US20020044930 Severe combined immunodeficiency disease (SCID); immunotherapy of human diseases such as prostate cancer |
| 04/18/2002 | US20020044928 Immunization of dairy cattle with chimeric GapC protein against streptococcus infection |
| 04/18/2002 | CA2785941A1 Antibody composition-producing cell |
| 04/18/2002 | CA2751188A1 Reduced-viscosity concentrated protein formulations |
| 04/18/2002 | CA2462671A1 Normalization of defective t cell responsiveness through manipulation of thymic regeneration |
| 04/18/2002 | CA2462073A1 Hematopoietic stem cell gene therapy |
| 04/18/2002 | CA2462046A1 Improvement of graft acceptance through manipulation of thymic regeneration |
| 04/18/2002 | CA2462027A1 Stimulation of thymus for vaccination development |
| 04/18/2002 | CA2425818A1 Novel human beta2 integrin alpha subunit |
| 04/18/2002 | CA2425809A1 Humanized anti-lt-.beta.-r antibodies |
| 04/18/2002 | CA2425767A1 Lipocalins |
| 04/18/2002 | CA2425643A1 Cancer-linked genes as targets for chemotherapy |
| 04/18/2002 | CA2425486A1 Flea peritrophin nucleic acid molecules, proteins and uses thereof |
| 04/18/2002 | CA2425356A1 Hedgehog antagonists, methods and uses related thereto |
| 04/18/2002 | CA2424987A1 Methods of agonizing and antagonizing fabk |
| 04/18/2002 | CA2424983A1 Nucleic acid molecules and polypeptides for immune modulation |
| 04/18/2002 | CA2424967A1 Complexes for transferring nucleic acids into cells |
| 04/18/2002 | CA2424946A1 Non typeable haemophilus influenzae basb201 polypeptides and encoding polynucleotides and uses thereof |
| 04/18/2002 | CA2424933A1 Haemophilus influenza basb203 polypeptides and encoding polynucleotides and uses thereof |
| 04/18/2002 | CA2424433A1 Bvh-a2 and bvh-a3 antigens of group b streptococcus |
| 04/18/2002 | CA2422881A1 Human anti-epidermal growth factor receptor single-chain antibodies |
| 04/18/2002 | CA2422718A1 Compositions and methods for prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with compositions comprising unfractionated cellular proteins |
| 04/17/2002 | EP1197550A2 Methods and compositions for diagnosing and treating disorders involving angiogenesis |
| 04/17/2002 | EP1197225A1 REMEDIES FOR DISEASES CAUSED BY PTH OR PTHrP |
| 04/17/2002 | EP1197224A1 Agents for ameliorating low vasopressin level |
| 04/17/2002 | EP1197220A2 Therapeutic methods and compositions based on delta proteins and nucleic acids |
| 04/17/2002 | EP1196782A1 Catalytic anti-factor viii allo-antibodies |
| 04/17/2002 | EP1196779A1 Determining antibodies to ny-eso-1 in cancer patients |
| 04/17/2002 | EP1196635A2 Cell death related drug targets in yeast and fungi |
| 04/17/2002 | EP1196609A2 Catalytically active recombinant memapsin and methods of use thereof |
| 04/17/2002 | EP1196608A2 Novel antifungal agents and fungicides, method for the production thereof and their use |
| 04/17/2002 | EP1196598A1 Dsp-3 dual-specificity phosphatase |
| 04/17/2002 | EP1196596A1 Mosaic infectious bursal disease virus vaccines |
| 04/17/2002 | EP1196595A2 Methods of inducing cell death |
| 04/17/2002 | EP1196591A1 Moraxella catarrhalis polypeptides |
| 04/17/2002 | EP1196588A1 Basb113 polypeptide antigen from moraxella catarrhalis |
| 04/17/2002 | EP1196587A2 Antigenic meningococcal peptides |
| 04/17/2002 | EP1196586A1 Basb111 polypeptide and polynucleotide from moraxella catharrhalis |
| 04/17/2002 | EP1196584A1 Tetanus toxin polypeptides |
| 04/17/2002 | EP1196579A2 Tryptase inhibitor |
| 04/17/2002 | EP1196575A2 Gtp-binding protein associated factors |
| 04/17/2002 | EP1196574A2 Human proteins involved in detoxification |
| 04/17/2002 | EP1196570A2 Human polypeptides and methods for the use thereof |
| 04/17/2002 | EP1196565A2 Compositions and methods for the therapy and diagnosis of lung cancer |
| 04/17/2002 | EP1196560A1 Neurotrophic factor receptor gfr-alpha-4 |
| 04/17/2002 | EP1196558A1 Immunostimulant oligonucleotide |
| 04/17/2002 | EP1196552A2 Methods and compositions for engineering of attenuated vaccines |
| 04/17/2002 | EP1196437A1 Fima PILUS-BASED VACCINES |
| 04/17/2002 | EP1196406A1 Amino ceramide-like compounds and therapeutic methods of use |
| 04/17/2002 | EP1196197A2 Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene |
| 04/17/2002 | EP1196193A2 Interleukin-1 muteins useful as vaccine adjuvants |
| 04/17/2002 | EP1196192A1 Method for enhancing an immune response |
| 04/17/2002 | EP1196191A1 Death domain containing receptor 5 |
| 04/17/2002 | EP1196188A1 Vgf selective binding agents and methods of treating vgf-related disorders |
| 04/17/2002 | EP1196186A2 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 04/17/2002 | EP1196031A1 Vaccine formulations and methods for immunizing an individual against shed antigen-specific b cells |
| 04/17/2002 | EP0793506B1 Cellular and serum protein anchors and conjugates |
| 04/17/2002 | EP0707485B1 Anti-cholesterolemic egg, vaccine and method for production, and use |
| 04/17/2002 | EP0662827B1 Diagnostic methods and pharmaceutical compositions based on notch proteins and nucleic acids |
| 04/17/2002 | EP0500785B1 A human t cell reactive feline protein (trfp) isolated from house dust and uses therefor |
| 04/17/2002 | EP0359783B2 Treatment of autoimmune diseases by oral administration of autoantigens |
| 04/17/2002 | CN1345375A Streptococcus pneumoniae antigens |
| 04/17/2002 | CN1345374A HER-2/neu fusion proteins |
| 04/17/2002 | CN1345370A Compartmentalization of recombinant polypeptides in host cells |
| 04/17/2002 | CN1345336A Antibody and chemokine constructs and their use for treating autoimmune diseases |
| 04/17/2002 | CN1345334A Antibodies specific to KDR and uses thereof |
| 04/17/2002 | CN1345331A Method and composition for angiogenesis inhibition |
| 04/17/2002 | CN1345329A Tumor mecrosis factor receptors 6 alpha and beta |
| 04/17/2002 | CN1345246A Compositions and method for prevention or treatment of cancer and bone loss associated with cancer |
| 04/17/2002 | CN1345242A Method for treatment of leukaemia |
| 04/17/2002 | CN1345232A Hydrogel particle formulations |
| 04/17/2002 | CN1344746A Prepn and application of individual antitumor specific antibody |
| 04/17/2002 | CN1082821C Antibody cojugates |
| 04/17/2002 | CN1082819C United pharmaceutical system for abrogation of viral resistance to nucleoside analogues by double-stranded RNAS |
| 04/16/2002 | US6372957 Transgenic mouse comprising a MEF2 binding site operatively linked to an indicator gene and methods of use |
| 04/16/2002 | US6372897 Mimotopic polypeptides of toxoplasma gondii and applications |
| 04/16/2002 | US6372884 Comparing amino acid sequences of complementarity-determining regions of an anti-receptor antibody that mimics or blocks a biologically active protein; identifying amino acid sequence in complementarity-determining region; synthesizing |
| 04/16/2002 | US6372490 Nucleic acid encoding the MDM interacting protein |
| 04/16/2002 | US6372487 Polynucleotides encoding peptide release factor, prfC (RF-3), a GTP-binding protein |
| 04/16/2002 | US6372478 Vaccine vehicles are useful for administration to mammalian hosts for purposes of immunization |
| 04/16/2002 | US6372473 Tissue plasminogen activator-like protease |
| 04/16/2002 | US6372471 Cloning and recombinant production of vespid venom enzymes, such as phospholipase and hyaluronidase, and immunological therapies based thereon |
| 04/16/2002 | US6372468 Useful in the development of human therapeutics and diagnostic formulations |
| 04/16/2002 | US6372454 Also vectors, host cells; screening methods for identifying agonists or antagonists of follistatin-3 activity; diagnostic methods for detecting reproductive system and cell differentiation disorders and treating these |
| 04/16/2002 | US6372443 Cassette for expressing a toxoplasma gondii P30 protein |
| 04/16/2002 | US6372441 Detecting the expression of the variable exon v10 in the cd44 gene in a patient or in a sample obtained from a patient, wherein the expression of the variable exon v10 in the cd44 gene indicates hodgkin's lymphomas |
| 04/16/2002 | US6372431 Mammalian toxicological response markers |
| 04/16/2002 | US6372260 Incorporation of active substances in carrier matrixes |
| 04/16/2002 | US6372258 Methods of spray-drying a drug and a hydrophobic amino acid |
| 04/16/2002 | US6372250 Non-invasive gene targeting to the brain |
| 04/16/2002 | US6372227 Oil in water emulsion containing a sterol and a saponin |